News & Media

SK life science

Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company

General business

Strategic alliance and partnership opportunities

Media inquiries and PR

Grant and investigator initiated proposals

Sponsorship requests

Medical information inquiries or report adverse events

SK life science at a glance

  • Headquarters location


  • R&D Begins


  • Parent Company

    SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group

  • Number of employees

    200+ EMPLOYEES

  • Disease Category Focus


  • Pipeline

    8 compounds under clinical development


SK Biopharmaceuticals’ 2022 Sustainability Report Reinforces its Commitment to ESG Management

Full release

Long-Term Efficacy and Safety Data of XCOPRI® (cenobamate tablets) CV Published in Neurology

Full release

SK Biopharmaceuticals Announces Social Value Performance for 2021

Full release

SK Biopharmaceuticals Partners with Cala to Fuel Innovation in Neurology

Full release

SK life science Presents Long-term Data on Cognitive and Psychiatric Adverse Events Associated with XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AAN 2022 Annual Meeting

Full release

SK life science to Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Academy of Neurology 2022 Annual Meeting

Full release

SK Biopharmaceuticals Becomes First Korean Company to Join Pharmaceutical Supply Chain Initiative

Full release

SK life science Announces FDA Clearance of IND Application for its Oncology Candidate, SKL27969, a PRMT5 Inhibitor for the Potential Treatment of Advanced Solid Tumors

Full release

SK life science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome

Full release

SK Biopharmaceuticals Enters into Licensing Agreement with Endo for Cenobamate in Canada

Full release